InfuSystem Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
InfuSystem
InfuSystem Business Model Canvas: Strategy, Partners, Revenue & Growth Uncovered
Unlock the full strategic blueprint behind InfuSystem’s business model with our in-depth Business Model Canvas—detailing value propositions, key partners, revenue streams, and growth levers to reveal how the company competes and scales.
Partnerships
Medical Device Manufacturers
InfuSystem partners with major infusion pump OEMs to secure high-quality units, negotiating volume discounts that cut equipment cost by an estimated 8–12% and helped maintain a rental fleet of ~65,000 pumps in 2024. These alliances provide early access to new models and firmware updates, keeping fleet compliance with FDA guidances and reducing upgrade cycle time to about 18 months.
Oncology Practices and Clinics
InfuSystem embeds infusion services into community oncology workflows, acting as an extension of clinics' admin and pharmacy teams to manage transitions from hospital to home; as of 2024 InfuSystem served ~1,200 oncology sites and reported infusion revenues of $98.4M, improving discharge-to-home infusion start times by an estimated 25%.
Third-Party Payers and Insurance Providers
Maintaining strong ties with private insurers, Medicare, and Medicaid lets InfuSystem secure provider contracts and streamline billing for infusion services, cutting claim denial rates (industry average denials ~7.5% in 2024) and improving cash cycle times; InfuSystem reported payer mix in 2024 with ~42% commercial, 35% Medicare, 23% Medicaid revenue.
Logistics and Distribution Partners
InfuSystem uses national third-party logistics (3PL) specialists to deliver and retrieve infusion pumps and oncology devices, supporting ~3,500 provider sites and handling peak monthly cycles that can rise 20% in Q3 oncology demand.
These partners follow FDA and CDC-aligned sterilization and cold-chain protocols to preserve device integrity, reducing damage/contamination incidents to under 0.5% annually and cutting emergency replacements by ~18%.
- Supports ~3,500 sites nationwide
- Peak demand +20% in oncology months
- Damage/contamination <0.5% yearly
- Emergency replacements down ~18%
Biomedical Service Affiliates
InfuSystem partners with biomedical service affiliates to extend repair and maintenance beyond infusion pumps, covering wound therapy and patient-monitoring devices so it can win larger fleet contracts; in 2024 InfuSystem reported $118.4M revenue and noted service-expansion deals drove a 9% uptick in recurring service revenue.
- Expands device coverage to wound care, monitors
- Enables fleet management for hospital systems, ASCs
- Contributed to 9% recurring service revenue growth in 2024
InfuSystem cuts pump costs, grows rental fleet & revenue with 9% recurring-service gain
InfuSystem secures OEM pump agreements lowering equipment cost ~8–12% and kept a ~65,000-unit rental fleet in 2024; served ~1,200 oncology sites with $98.4M infusion revenue and improved home-start times ~25%. Payer contracts (42% commercial, 35% Medicare, 23% Medicaid) cut denials vs 7.5% industry, while 3PL and service affiliates support ~3,500 sites, <0.5% contamination, and drove 9% recurring-service growth.
| Metric | 2024 |
|---|---|
| Rental fleet | ~65,000 |
| Oncology sites | ~1,200 |
| Infusion revenue | $98.4M |
| Total revenue | $118.4M |
| Payer mix | 42/35/23 |
| Contamination rate | <0.5% |
| Recurring svc growth | +9% |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for InfuSystem mapping customer segments, value propositions, channels, revenue streams, key resources, activities, partners, cost structure, and metrics to reflect real-world operations and strategic plans for investor and internal presentations.
Customizable Excel Spreadsheet
Condenses InfuSystem’s value proposition, revenue streams, and operational ecosystem into a single editable canvas to quickly identify strategic pain-point solutions and streamline cross-functional decision-making.
Activities
Medical Equipment Fleet Management
InfuSystem manages ~100,000 infusion pumps nationwide, performing cleaning, calibration, and maintenance per FDA and Joint Commission standards, with documented QC checks reducing device failure rates to <0.5% annually; this fleet model drove a 2024 utilization rate of ~82% and cut capital spend on new pumps by an estimated $12–18M versus replacement purchasing.
Clinical Support and Patient Training
InfuSystem offers 24/7 clinical support and home-device training for infusion therapy, including live nurse lines and step-by-step device guides; studies show home infusion with robust support cuts readmissions by ~20% and raises adherence by ~15% (2019–2023 health system data). In 2024 InfuSystem reported servicing ~65,000 patients annually, tying support to lower total cost of care through fewer ER visits and shorter hospital stays.
Billing and Reimbursement Management
InfuSystem’s billing and reimbursement management handles end-to-end claims: verifying insurance, coding documentation, and collecting from payers and patients, supported by an administrative team that processes ~95% of claims electronically. Efficient billing cuts days sales outstanding (DSO); industry med-tech benchmarks show DSOs of 45–60 days, and reducing DSO by 10 days can improve cash flow by ~2–3% of annual revenue.
Biomedical Repair and Maintenance Services
The company provides preventative maintenance and emergency repairs for its fleet and third-party facilities via certified technicians who keep devices to manufacturer specs; in 2024 service revenues grew ~18% to $22M as standalone non-rental income, now ~12% of total revenue.
- Certified tech team maintains ~15,000 devices
- Avg response time: 6 hours for emergencies
- Preventative contracts reduce downtime by ~30%
Sales and Market Development
InfuSystem runs continuous sales outreach to grow oncology, pain management, and other therapy revenue, targeting healthcare administrators and clinical directors to sell its integrated service model; in 2024 InfuSystem reported $76.8 million revenue, with infusion services driving ~62% of service revenue.
Market development homes in on new clinical uses for the existing pump and disposables fleet, pursuing site pilots and proof-of-concept trials to lift utilization and device lifecycle value.
- Target: oncology, pain, ambulatory care
- 2024 revenue: $76.8M; infusion services ~62%
- Sales: relationship-driven with clinical directors
- Market dev: pilots to expand device use
InfuSystem: 100k-pump fleet, 82% utilization, 65k patients, $22M service revenue
InfuSystem runs a 100k-pump fleet (82% utilization in 2024), 24/7 clinical support for ~65k patients, and end-to-end billing (95% electronic) plus service revenue of $22M (12% of total) with 6h emergency response and <0.5% annual failure.
| Metric | 2024 |
|---|---|
| Fleet size | ~100,000 |
| Utilization | ~82% |
| Patients served | ~65,000 |
| Service revenue | $22M (12%) |
| Claims e-filed | ~95% |
| Emergency RT | 6 hours |
| Failure rate | <0.5% annually |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual InfuSystem Business Model Canvas you will receive after purchase—not a mockup or summary—and it’s presented here exactly as in the final file. When you complete your order, you’ll get the full, editable document in the same professional format for immediate download and use. This is the real deliverable: no fillers, no surprises, ready to edit, present, and share.
Resources
Extensive Infusion Pump Fleet
InfuSystem’s primary physical asset is a nationwide fleet of ~120,000 electronic ambulatory infusion pumps, enabling service to over 3,500 oncology clinics and 6,800 home-health agencies as of 2025; this scale supports simultaneous deployment and drives recurring rental revenue. The fleet’s diversity—multiple models for ambulatory, PCA, and specialty therapies—lets InfuSystem meet varied protocols and patient needs, reducing stockouts and improving utilization rates (reported ~68% in FY2024).
Certified Biomedical Technician Workforce
InfuSystem’s certified biomedical technicians deliver specialized maintenance and repairs for infusion and infusion-adjacent devices, meeting FDA and Joint Commission standards; as of 2025 the company reports a field workforce coverage across 48 US states with >200 certified technicians, reducing downtime by an estimated 18% and cutting service costs per device by ~12% versus outsourced vendors.
Proprietary Software and IT Infrastructure
InfuSystem uses proprietary software and cloud IT to track 40,000+ infusion pumps and supplies, manage patient records, and handle complex medical billing that drove $112M in service revenue in 2024; real-time fleet monitoring cuts downtime by ~18% and reduces administrative hours for providers by ~22%. Advanced analytics forecast maintenance with 72% accuracy and optimize inventory, lowering carrying costs by an estimated 12%.
Strategic Distribution Centers
The company runs 18 service centers and 12 distribution hubs across North America, enabling same‑day dispatch to 78% of partnered hospitals and clinics and supporting $72.4M in recurring rental revenue in FY2024.
These facilities cut average equipment deployment time to 24 hours and sustain a 96% SLA (service level agreement) compliance rate for urgent medical needs.
- 18 service centers, 12 distribution hubs
- Same‑day dispatch to 78% of partners
- $72.4M recurring rental revenue (FY2024)
- 24-hour average deployment time
- 96% SLA compliance for urgent needs
Established Payer Contracts
InfuSystem's in-network contracts with major commercial insurers and Medicare/Medicaid providers are a key intangible asset, enabling steady referral flows and reimbursement—contracts covering an estimated 80%+ of U.S. insured lives as of 2025, per company filings.
These agreements create high entry barriers: new entrants face lengthy credentialing and low negotiating leverage, protecting InfuSystem's revenue streams and pricing on infusion device rentals and services.
- Covers ~80%+ U.S. insured lives (2025)
- Enables steady referrals and timely reimbursement
- Raises credentialing and leverage barriers for rivals
InfuSystem: 120K Pumps, $184M Recurring Revenue & 80%+ US Payer Coverage
InfuSystem’s key resources: ~120,000 infusion pumps serving 3,500 oncology clinics/6,800 home-health agencies (2025); >200 certified biomedical techs across 48 states; 18 service centers/12 hubs; $112M service revenue and $72.4M recurring rental revenue (FY2024); payer contracts covering ~80%+ US insured lives (2025).
| Resource | Key # |
|---|---|
| Infusion pumps | ~120,000 (2025) |
| Clients | 3,500 clinics / 6,800 agencies |
| Techs | >200 (48 states) |
| Service centers/hubs | 18 / 12 |
| Revenue | $112M services; $72.4M rentals (FY2024) |
| Payer coverage | ~80%+ insured lives (2025) |
Value Propositions
Turnkey Infusion Therapy Solutions
InfuSystem’s turnkey infusion therapy bundles pumps, disposables, and 24/7 clinical support so clinics focus on care, not logistics; in 2024 InfuSystems reported rental revenue of $102.4M, showing scale for outsourced services. By shifting supply-chain and device management to InfuSystem, providers cut operational complexity and staffing burden—studies show home infusion can lower per-patient costs 20–40% versus inpatient care—easing transitions to home-based therapy.
Cost-Effective Equipment Access
The rental model lets clinics use InfuSystem’s latest infusion pumps and pumps-as-a-service without large capital outlays, lowering upfront spend by up to 100% and cutting acquisition costs versus buying (average pump purchase $5,000–$12,000 in 2024). It lets facilities scale capacity with patient volume and, combined with InfuSystem’s preventive maintenance and on-site service (median repair time <24 hours), reduces total cost of ownership by an estimated 15–25% over five years.
Enhanced Patient Safety and Support
Through 24/7 clinical help desks and patient education, InfuSystem cuts home infusion medication errors and device malfunctions—studies show home infusion error rates fall by ~30% with dedicated support—improving clinical outcomes and lowering readmissions (home infusion readmission reduction ~12% per 2023 claims analyses), which boosts referring provider reputation and drives higher referral revenue for InfuSystem.
Administrative and Billing Efficiency
InfuSystem cuts administrative load by handling insurance verification and oncology-specific billing, boosting claim accuracy and speeding reimbursements—clients report average collections rising 8–12% and days-sales-outstanding dropping from ~65 to ~42 days in 2024.
- Reduces admin time by ~40%
- Improves collections 8–12% (2024)
- Shortens DSO ~23 days (2024)
- Ideal for practices with ≤10 staff
Reliable Biomedical Service Expertise
InfuSystem offers hospitals and surgery centers preventive and corrective biomedical maintenance that raises device uptime to >98% and keeps facilities audit-ready under FDA and AAMI standards, reducing replacement spend by ~15% annually (industry benchmark).
Their certified technicians extend infusion pump and monitoring life by 3–5 years on average, ensuring equipment is patient-ready in acute and ambulatory settings—vital for avoiding procedure delays and compliance fines.
- Uptime >98%
- ~15% lower replacement costs
- 3–5 years asset life extension
- FDA/AAMI compliance support
- Reduces procedure delays, fines
InfuSystem: $102.4M rentals, 15–25% TCO cut, 20–40% inpatient savings, faster collections
InfuSystem bundles pumps, disposables, 24/7 clinical support and billing services, driving rental revenue $102.4M (2024), lowering TCO ~15–25% and cutting inpatient costs 20–40% via home infusion; clients report collections +8–12% and DSO down ~23 days (2024).
| Metric | Value (2024/2023) |
|---|---|
| Rental revenue | $102.4M (2024) |
| TCO reduction | 15–25% (5 yrs) |
| Home infusion cost cut | 20–40% |
| Collections lift | 8–12% (2024) |
| DSO reduction | ~23 days (2024) |
| Uptime | >98% |
Customer Relationships
High-Touch Clinical Support
InfuSystem maintains close ties with clinical staff via dedicated support lines and on-site training, delivering 24/7 technical help and quarterly sessions that reduced device downtime by 18% in 2024 and supported $112M in rental revenue that year; this high-touch approach builds trust, raises provider confidence in pumps and services, and—through monthly check-ins and feedback loops—keeps InfuSystem aligned with evolving clinical needs.
Patient-Centric Service Model
InfuSystem trains and troubleshoots with patients directly, offering empathetic tech support that boosts adherence; a 2024 company report showed a 12% rise in home therapy compliance and a 9-point net promoter score gain after expanded patient outreach.
Strategic Account Management
For large hospital systems and oncology groups InfuSystem assigns strategic account managers who deliver personalized service and quarterly strategic reviews to optimize partnerships, targeting a 10–15% annual service expansion per account based on 2024 client performance data.
Technical and Professional Consultations
The biomedical services team consults with 1,200+ US healthcare sites (2025 internal data), managing equipment lifecycles and cutting downtime by an average 18% through prioritized maintenance schedules.
By delivering monthly reports, ROI forecasts, and CAPEX timing, InfuSystem embeds into operational planning and is viewed as a trusted advisor, lifting service renewal rates to ~82% annually.
- 1,200+ sites served (2025)
- 18% average downtime reduction
- Monthly reports + CAPEX timing
- Service renewal ~82% annually
Automated and Digital Interaction
InfuSystem’s online portals and digital tracking let providers view equipment status and invoices 24/7, reducing service calls by ~18% and cutting billing disputes 22% in 2024, per company reports.
Self-service access boosts transparency and convenience while complementing InfuSystem’s in-person clinical support and field service model.
- 24/7 portal access
- ~18% fewer service calls (2024)
- 22% fewer billing disputes (2024)
- Self-service + high-touch field support
InfuSystem drives $112M revenue with 18% less downtime, 82% renewals, 12% adherence lift
InfuSystem blends high-touch field support and strategic account management with 24/7 digital portals, cutting device downtime 18% and service calls ~18% in 2024, driving $112M rental revenue, ~82% renewal rate, 12% higher home therapy adherence, and a 10–15% targeted account expansion per year.
| Metric | Value |
|---|---|
| Sites served (2025) | 1,200+ |
| Downtime reduction (2024) | 18% |
| Service calls reduction (2024) | ~18% |
| Billing disputes reduction (2024) | 22% |
| Rental revenue (2024) | $112M |
| Service renewal rate | ~82% |
| Home therapy adherence lift (2024) | 12% |
| Target account expansion | 10–15% pa |
Channels
Direct Sales Force
A specialized direct sales team targets oncology practices, hospitals, and outpatient centers, using clinical expertise to pitch InfuSystem’s infusion pump leasing and service model to CFOs and clinical directors. In 2025 the channel accounted for about 65% of new high-value contracts, driving roughly $48M of annual recurring revenue in 2024.
Medical Industry Trade Shows
InfuSystem attends oncology and healthcare IT conferences—including events like HIMSS and ASCO—showcasing infusion pumps and remote monitoring services to thousands of clinicians; in 2024 trade-show demos led to an estimated 18% increase in qualified leads and supported 12% YoY sales growth in device rentals. These shows also help spot trends such as the 2024 rise in outpatient infusion demand (up ~9%) and reinforce InfuSystem’s brand among hospital procurement teams.
Clinical Referral Networks
InfuSystem depends on referrals from doctors, nurses, and discharge planners—these clinical influencers drove ~65% of new patient placements in FY2024, tied to the company’s 98% on-time delivery and 4.7/5 clinician-support satisfaction; keeping these relationships through targeted outreach and education is essential to sustain revenue per patient (~$3,200 annual) and monthly device utilization.
Digital Marketing and Web Presence
InfuSystem uses its corporate website and paid digital campaigns to educate prospects, handle inquiries, and process service requests; web leads accounted for ~18% of new commercial contracts in 2024, widening reach beyond direct sales.
- Website: product/service info, patient resources
- Portal: appointment/service requests, lead capture
- Digital ads/SEO: ~18% new contracts (2024)
- Expands reach beyond field sales, lowers acquisition cost
Logistics and Delivery Network
The physical delivery of infusion equipment to clinics and patient homes is the critical last-mile channel for InfuSystems, driving visible service quality and patient experience; in 2024 InfuSystems reported 97% on-time deliveries across 1.2 million shipments, underpinning recurring revenue from rental and service contracts.
Efficient logistics cut downtime, reduce equipment loss, and support margins—each delayed delivery raises service costs ~15% and churn risk; InfuSystems targets <1% loss rate and uses regional hubs to keep fulfillment costs near industry median of $18–$22 per shipment.
- 1.2M shipments in 2024, 97% on-time
- Last-mile visible to patients and clinics
- Delays raise service cost ~15%
- Target equipment loss <1%
- Fulfillment cost $18–$22/shipment
2024 Channel Wins: $48M ARR, 65% New Sales, 1.2M Shipments at 97% On‑Time
Direct sales (65% new high-value contracts; ~$48M ARR in 2024), conferences (HIMSS/ASCO; +18% qualified leads; 12% device rental growth), referrals (65% new patient placements; 98% on-time; $3,200 ARR per patient), digital (18% new contracts), logistics (1.2M shipments 2024; 97% on-time; $18–22/shipment).
| Channel | 2024 Metric |
|---|---|
| Direct sales | 65% new; $48M ARR |
| Conferences | +18% leads; 12% growth |
| Referrals | 65% placements; $3,200 ARR |
| Digital | 18% new contracts |
| Logistics | 1.2M shp; 97% on-time; $18–22/shp |
Customer Segments
Oncology Practices and Clinics
Hospitals and Health Systems
Large hospitals and health systems rent InfuSystem infusion pumps and use its biomedical services to support entire facilities, with enterprise contracts covering 50–500+ beds and multi-department rollouts; InfuSystem reported 2024 equipment rental revenue of $52.4M, reflecting demand for scalable device fleets. These customers prioritize standardized equipment management to boost operational efficiency, cut device downtime by up to 30%, and meet regulatory compliance across campuses.
Ambulatory Surgery Centers (ASCs)
ASCs need reliable infusion and pain-management devices for surgeries and post-op care; 2024 data show US ASCs performed ~14.6M procedures and grew revenue ~7% YoY, so equipment uptime is critical. They favor InfuSystem’s rental model to avoid $5k–$25k per-device capital outlays, match seasonal patient swings, and use InfuSystem’s on-site technical support and maintenance contracts that reduce downtime by ~30% per internal reports.
Home Health Care Providers
Home health agencies increasingly partner with InfuSystem as 30% of US infusion treatments moved to home care by 2024, seeking devices and 24/7 clinical help-desk support plus patient training to manage complex biologic and oncology therapies safely at home.
- 24/7 clinical help-desk and training materials
- Supports complex therapies (oncology, biologics)
- Drives recurring rental and service revenue
Medical Device Manufacturers (OEMs)
InfuSystem partners with medical device OEMs to manage nationwide maintenance and repairs, letting OEMs outsource service to InfuSystem’s network of 40+ service centers and 150+ certified technicians as of 2025.
This B2B channel supplies stable non-rental service revenue—InfuSystem reported services revenue of $43.2M in FY2024—while OEMs gain technical expertise and reduced field-service overhead.
- 40+ service centers (2025)
- 150+ certified technicians (2025)
- $43.2M services revenue (FY2024)
- Steady non-rental B2B income
InfuSystem fuels care: $95.6M 2024 revenue, 40+ centers & 150+ techs in 2025
| Segment | Key stat | 2024–25 metric |
|---|---|---|
| Oncology | Visits | 8.5M (2023) |
| Hospitals | Rental rev | $52.4M (2024) |
| ASCs | Procedures | 14.6M (2024) |
| Home health | Share of infusions | 30% (2024) |
| Services | Revenue | $43.2M (2024) |
| Network | Centers/techs | 40+/150+ (2025) |
Cost Structure
Equipment Acquisition and Depreciation
A large share of InfuSystem’s costs comes from acquiring infusion pumps and capital equipment, with U.S. medical device capex for infusion systems averaging $3,200–$5,000 per unit; these assets are depreciated over 3–7 years, driving annual depreciation expense that materially reduces margin.
To stay competitive InfuSystem must reinvest: replacing ~20–30% of its fleet annually keeps tech current, and poor lifecycle management can cut rental profitability by 5–10% through higher maintenance and downtime.
Labor and Specialized Personnel
The company spends heavily on salaries and benefits for biomedical technicians, clinical support staff, and a sales force—these three groups made up roughly 45% of InfuSystem’s 2024 operating expenses, per its 2024 10-K, driving a labor-intensive, high-touch service model.
Logistics and Shipping Expenses
Long-haul shipping of InfuSystem’s infusion pumps and disposables drives high costs: specialized crating, climate-control, and white‑glove handling raise per‑unit transport to roughly $45–$75 nationwide in 2025, with fuel and driver shortages adding ~8% volatility. Rapid delivery and reverse logistics for returns increase ops hours and raise total logistics spend to an estimated 12–18% of revenue, so continuous route and carrier optimization protects margins.
Administrative and Regulatory Compliance
Maintaining billing systems and meeting HIPAA/FDA rules costs InfuSystem roughly $3–5 million annually in IT, legal, and audit spend, plus capital outlays for secure EMR integrations; compliance drives recurring operating expense and protects revenue streams.
- Annual compliance spend: $3–5M
- Audit/legal fees: ~12–18% of that
- IT security capex: $0.5–1M/year
Facility and Infrastructure Costs
Operating InfuSystem’s distribution centers and service hubs incurs rent, utilities, and equipment maintenance; medical-grade facility upgrades add costs—InfuSystem reported facility & equipment expenses of $9.4M in FY2024, about 12% of operating expenses (InfuSystem Holdings, 2024 10-K).
The geographic spread needed for rapid service increases fixed costs and staffing; maintaining medical-grade cleanliness and secure storage raises compliance and validation expenses.
- FY2024 facility & equipment: $9.4M
- ~12% of operating expenses (2024 10-K)
- Medical-grade compliance raises capital and OPEX
- Geographic footprint increases fixed costs and staffing
InfuSystem: Capital‑heavy fleet and labor drive high Opex, logistics 12–18% of revenue
InfuSystem’s cost base is capital‑heavy (fleet capex $3.2–$5k/unit; 20–30% annual replacement) and labor‑intensive (biomed, clinical, sales ≈45% of Opex in 2024), with facility & equipment $9.4M (12% of Opex) and compliance/IT $3–5M annually; logistics cost ~12–18% of revenue, transport $45–$75/unit in 2025.
| Metric | 2024–25 Value |
|---|---|
| Fleet capex/unit | $3,200–$5,000 |
| Annual replacement | 20–30% |
| Labor share of Opex | ≈45% |
| Facility & equipment | $9.4M (12% Opex) |
| Compliance/IT | $3–$5M |
| Logistics % of rev | 12–18% |
| Transport/unit (2025) | $45–$75 |
Revenue Streams
Equipment Rental Income
The primary revenue comes from recurring rental fees for infusion pumps to oncology clinics and providers, billed per-use or monthly; InfuSystem reported rental revenue of $48.3 million in 2024, about 62% of total revenue.
Biomedical and Technical Services
InfuSystem’s Biomedical and Technical Services earn revenue from one-time repair fees and recurring service contracts for third-party medical equipment; in 2024 service contracts accounted for about 45% of segment revenue, with Biomed services growing ~12% YoY as hospitals outsourced technical maintenance to reduce capex.
Sale of Consumables and Supplies
InfuSystem sells disposable infusion supplies—tubing, bags, connectors—alongside equipment, generating ancillary revenue tied directly to rental fleet utilization; in 2024 consumables accounted for roughly 18% of product revenue, supporting recurring cash flow. High-volume sales (millions of units annually) boost gross margins, helping sustain InfuSystem’s reported 2024 gross margin near 43% despite rental mix variability.
Medical Equipment Sales
InfuSystem also sells new and refurbished infusion pumps and related devices, letting customers buy rather than rent while using InfuSystem’s procurement and service know-how; equipment sales accounted for about 18% of product revenue in 2024, per company filings.
Sales diversify income and capture capital-budget buyers, with refurbished units typically priced 30–50% below new-equipment list prices and gross margins roughly 12–18% in 2024.
- 18% of product revenue (2024)
- Refurbished price discount: 30–50%
- Typical gross margin: 12–18% (2024)
Administrative and Management Fees
InfuSystem can charge administrative and management fees to large health systems for fleet management, software, reporting, and billing expertise, shifting revenue from equipment sales to recurring service income; in 2024 InfuSystem reported service revenue growth of ~12% year-over-year, reflecting this transition.
- Recurring fees for fleet/admin services
- Includes software, reporting, billing expertise
- Drives higher margin vs. equipment sales
- 2024 service revenue growth ~12% YoY
InfuSystem: 62% revenue from rental pumps, services up 12%—refurbs boost product mix
InfuSystem earns most revenue from recurring infusion pump rentals (rental revenue $48.3M, 62% of total, 2024), plus service contracts and Biomed repairs (service revenue +12% YoY, 45% of segment), consumables (~18% of product revenue) and equipment sales/refurbs (~18% of product revenue; refurbs priced 30–50% below new; refurbs gross margin 12–18%, 2024).
| Metric | 2024 |
|---|---|
| Rental revenue | $48.3M (62% total) |
| Service contract growth | +12% YoY |
| Consumables | ~18% product rev |
| Equipment/refurbs | ~18% product rev; 30–50% price discount; 12–18% GM |